600276 恒瑞医药
午间休市 06-18 11:29:59
资讯
新帖
简况
施罗德增持恒瑞医药(01276)94.88万股 每股作价约54.54港元
智通财经 · 06-17 19:43
施罗德增持恒瑞医药(01276)94.88万股 每股作价约54.54港元
恒瑞医药(01276)6月17日斥资约562.45万元回购12万股A股
智通财经 · 06-17 16:56
恒瑞医药(01276)6月17日斥资约562.45万元回购12万股A股
恒瑞医药获NMPA批准 达匹昔利布伊塞酸盐片新适应症 CDK4/6抑制剂再获认可
美股速递 · 06-16 21:33
恒瑞医药获NMPA批准 达匹昔利布伊塞酸盐片新适应症 CDK4/6抑制剂再获认可
恒瑞医药：HRS-7525片获临床试验批准
南方财经网 · 06-16 17:03
恒瑞医药：HRS-7525片获临床试验批准
2026 EULAR︱恒瑞医药IFNAR1/TACI抗体融合蛋白SHR-2173治疗系统性红斑狼疮I期研究结果精彩亮相
恒瑞医药官微 · 06-11
2026 EULAR︱恒瑞医药IFNAR1/TACI抗体融合蛋白SHR-2173治疗系统性红斑狼疮I期研究结果精彩亮相
恒瑞医药三款新药获批临床，创新研发再添新进展｜医药早参
每日经济新闻 · 06-11
恒瑞医药三款新药获批临床，创新研发再添新进展｜医药早参
恒瑞医药(01276)6月10日斥资46.04万元回购1万股A股
智通财经 · 06-10
恒瑞医药(01276)6月10日斥资46.04万元回购1万股A股
恒瑞医药：2025年公司实现营业收入316.29亿元，同比增长13.02%
证券日报 · 06-09
恒瑞医药：2025年公司实现营业收入316.29亿元，同比增长13.02%
恒瑞医药及子公司三款药物获批临床
财中社 · 06-09
恒瑞医药及子公司三款药物获批临床
恒瑞医药(01276)6月9日斥资319.36万元回购7万股A股
智通财经 · 06-09
恒瑞医药(01276)6月9日斥资319.36万元回购7万股A股
恒瑞医药(01276)6月8日斥资2042.57万元回购44.4万股A股
智通财经 · 06-08
恒瑞医药(01276)6月8日斥资2042.57万元回购44.4万股A股
港股异动 | 恒瑞医药(01276)涨超5% “双艾”组合联合TACE治疗不可切除肝癌Ⅲ期研究结果亮相ASCO年会
智通财经 · 06-05
港股异动 | 恒瑞医药(01276)涨超5% “双艾”组合联合TACE治疗不可切除肝癌Ⅲ期研究结果亮相ASCO年会
恒瑞医药(01276)6月4日斥资1982.37万元回购42万股A股
智通财经 · 06-04
恒瑞医药(01276)6月4日斥资1982.37万元回购42万股A股
美团、京东、阿里、腾讯，集体下跌
第一财经 · 06-03
美团、京东、阿里、腾讯，集体下跌
恒瑞医药(01276)：截至5月末公司累计回购A股股份1205.62万股
智通财经 · 06-02
恒瑞医药(01276)：截至5月末公司累计回购A股股份1205.62万股
恒瑞医药累计回购1206万股 金额7.72亿元
财中社 · 06-02
恒瑞医药累计回购1206万股 金额7.72亿元
恒瑞医药：公司坚持科技创新与国际化发展战略，致力于发展好主营业务
证券日报 · 06-01
恒瑞医药：公司坚持科技创新与国际化发展战略，致力于发展好主营业务
恒瑞医药：公司将继续大力推进“科技创新”和“国际化”两大发展战略
证券日报 · 05-29
恒瑞医药：公司将继续大力推进“科技创新”和“国际化”两大发展战略
恒瑞医药：公司本轮回购期限为自2025年8月20日董事会审议通过回购股份方案之日起12个月以内，目前本次回购尚未结束
证券日报 · 05-29
恒瑞医药：公司本轮回购期限为自2025年8月20日董事会审议通过回购股份方案之日起12个月以内，目前本次回购尚未结束
恒瑞医药：公司目前已在中国获批上市25款1类创新药、5款2类新药
证券日报 · 05-29
恒瑞医药：公司目前已在中国获批上市25款1类创新药、5款2类新药
公司概况
公司名称：
江苏恒瑞医药股份有限公司
所属行业：
医药制造业
上市日期：
2000-10-18
主营业务：
江苏恒瑞医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是马来酸吡咯替尼片、注射用卡瑞利珠单抗、瑞维鲁胺片、海曲泊帕乙醇酰胺片、羟乙磺酸达尔西利片、碘佛醇注射液。自2019年起，公司连续七年跻身美国《制药经理人》(PharmExec)杂志评选的全球制药企业50强榜单。
发行价格：
11.98
{"stockData":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恒瑞医药","latestPrice":48.95,"timestamp":1781753399000,"preClose":46.99,"halted":0,"volume":91427951,"delay":0,"changeRate":0.0417,"floatShares":6379000000,"shares":6637000000,"eps":1.2233,"marketStatus":"午间休市","change":1.96,"latestTime":"06-18 11:29:59","open":46.99,"high":49.5,"low":46.61,"amount":4428000000,"amplitude":0.0615,"askPrice":48.95,"askSize":104,"bidPrice":48.94,"bidSize":170,"shortable":0,"etf":0,"ttmEps":1.2233,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1781758800000},"marketStatusCode":3,"adr":0,"adjPreClose":46.99,"symbolType":"stock","openAndCloseTimeList":[[1781746200000,1781753400000],[1781758800000,1781766000000]],"highLimit":51.69,"lowLimit":42.29,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":6637199874,"isCdr":false,"pbRate":4.9,"roa":"--","peRate":40.014714,"roe":"4.15%","epsLYR":1.19,"committee":-0.129436,"marketValue":324891000000,"turnoverRate":0.0143,"status":0,"hkstockBrief":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"恒瑞医药","latestPrice":54.45,"timestamp":1781755500003,"preClose":53,"halted":0,"volume":2618526,"delay":0,"premium":"-4.01"},"floatMarketCap":312252000000},"requestUrl":"/m/hq/s/600276/wiki","defaultTab":"wiki","newsList":[{"id":"2644745377","title":"施罗德增持恒瑞医药(01276)94.88万股 每股作价约54.54港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2644745377","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644745377?lang=zh_cn&edition=full","pubTime":"2026-06-17 19:43","pubTimestamp":1781696627,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，6月12日，施罗德增持恒瑞医药(01276)94.88万股，每股作价54.5391港元，总金额约为5174.67万港元。增持后最新持股数目约为1320.22万股，持股比例为5.11%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455720.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2495084118.USD","LU2097828714.EUR","LU1997245094.SGD","LU2097828631.EUR","BK0012","BK0028","LU2097828557.USD","BK0239","LU2488822045.USD","LU2097828805.USD","LU2148510915.USD","EWH","LU1580142542.USD","LU1064130708.USD","LU1146622755.USD","LU0359201612.USD","LU1023057109.AUD","LU0405327494.USD","LU2328871848.SGD","LU0359202008.SGD","LU1997245177.USD","LU1655091616.SGD","BK1191","LU1997244956.HKD","LU1255011170.USD","LU0405327148.USD","LU2580892789.USD","01276","LU2097828474.EUR","LU1328615791.USD","LU1820825898.SGD","BK0196","BK0060","LU1969619763.USD","LU2580892862.HKD","BK0188","BK0183","LU1781817850.SGD","LU2289578879.USD","600276","LU1064131003.USD","LU0359201885.HKD","LU2543165471.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644714982","title":"恒瑞医药(01276)6月17日斥资约562.45万元回购12万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2644714982","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644714982?lang=zh_cn&edition=full","pubTime":"2026-06-17 16:56","pubTimestamp":1781686567,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，于2026年6月17日该公司斥资约人民币562.45万元回购12万股A股，回购价格为每股人民币46.85至46.88元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455538.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2580892862.HKD","LU2097828557.USD","LU2097828474.EUR","LU0359202008.SGD","LU1146622755.USD","600276","BK0196","LU2543165471.USD","BK1191","LU1255011170.USD","LU0359201885.HKD","LU2495084118.USD","LU2148510915.USD","LU2097828714.EUR","LU2488822045.USD","LU2097828631.EUR","LU2580892789.USD","399300","LU0405327494.USD","LU0359201612.USD","LU1064131003.USD","LU1023057109.AUD","LU1997245094.SGD","159982","LU2097828805.USD","LU1328615791.USD","LU2289578879.USD","BK0012","BK0188","BK0239","LU1655091616.SGD","LU1997245177.USD","LU2328871848.SGD","BK0183","LU1969619763.USD","BK0028","LU1064130708.USD","LU1820825898.SGD","LU0405327148.USD","01276","BK0060","LU1580142542.USD","LU1781817850.SGD","LU1997244956.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184570619","title":"恒瑞医药获NMPA批准 达匹昔利布伊塞酸盐片新适应症 CDK4/6抑制剂再获认可","url":"https://stock-news.laohu8.com/highlight/detail?id=1184570619","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184570619?lang=zh_cn&edition=full","pubTime":"2026-06-16 21:33","pubTimestamp":1781616795,"startTime":"0","endTime":"0","summary":"恒瑞医药宣布，其创新药物达匹昔利布伊塞酸盐片（一种CDK4/6抑制剂）已收到国家药品监督管理局（NMPA）关于新适应症的批准通知。这一进展标志着该药物在临床应用范围上的进一步拓展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2148510915.USD","LU1328615791.USD","LU2097828805.USD","LU2097828631.EUR","LU1997245177.USD","BK0196","LU1146622755.USD","BK0188","BK0239","600276","BK0028","LU1023057109.AUD","LU1064130708.USD","LU2289578879.USD","BK0012","LU1997244956.HKD","LU0359201885.HKD","LU2543165471.USD","LU2580892862.HKD","LU1064131003.USD","LU2097828557.USD","LU2495084118.USD","LU2580892789.USD","LU2328871848.SGD","01276","LU1997245094.SGD","BK0060","LU2488822045.USD","LU0405327148.USD","LU0359202008.SGD","LU2097828474.EUR","LU0405327494.USD","LU2097828714.EUR","LU1969619763.USD","BK0183","LU1255011170.USD","LU1655091616.SGD","LU1580142542.USD","BK1191","LU1781817850.SGD","LU1820825898.SGD","LU0359201612.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643730703","title":"恒瑞医药：HRS-7525片获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2643730703","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643730703?lang=zh_cn&edition=full","pubTime":"2026-06-16 17:03","pubTimestamp":1781600580,"startTime":"0","endTime":"0","summary":"南财智讯6月16日电，恒瑞医药公告，HRS-7525片收到国家药品监督管理局签发的《药物临床试验批准通知书》，审批结论为同意该药单药在晚期实体瘤中开展临床试验；受理号为CXHL2600319、CXHL2600320，申请事项为临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606163773104428.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1655091616.SGD","LU2289578879.USD","LU1997244956.HKD","LU2580892862.HKD","LU1023057109.AUD","LU1328615791.USD","LU1146622755.USD","LU1580142542.USD","LU2580892789.USD","LU1997245177.USD","LU1969619763.USD","LU2543165471.USD","BK0060","BK0239","LU2097828474.EUR","BK0196","BK0183","LU2495084118.USD","LU1064131003.USD","LU0359201612.USD","LU2328871848.SGD","BK0028","LU1820825898.SGD","LU2097828631.EUR","LU1997245094.SGD","LU1255011170.USD","LU1781817850.SGD","LU2097828805.USD","LU0359202008.SGD","LU1064130708.USD","01276","LU0405327494.USD","LU0405327148.USD","LU2097828557.USD","LU2488822045.USD","BK1191","LU0359201885.HKD","LU2148510915.USD","600276","LU2097828714.EUR","BK0012","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642118285","title":"2026 EULAR︱恒瑞医药IFNAR1/TACI抗体融合蛋白SHR-2173治疗系统性红斑狼疮I期研究结果精彩亮相","url":"https://stock-news.laohu8.com/highlight/detail?id=2642118285","media":"恒瑞医药官微","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642118285?lang=zh_cn&edition=full","pubTime":"2026-06-11 18:12","pubTimestamp":1781172720,"startTime":"0","endTime":"0","summary":"2026年欧洲抗风湿病联盟年会已于当地时间6月3日至6日在英国伦敦隆重召开。期间，恒瑞医药自主研发的IFNAR1/TACI抗体融合蛋白SHR-2173用于系统性红斑狼疮的一项多中心、开放标签、多剂量递增I期临床研究成果精彩亮相1。目前，针对上述任一通路的单靶点治疗均难以实现整体病情的有效控制。各组均无导致试验终止的TEAE。本研究的初步临床证据为SHR-2173的持续开发提供了重要依据。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-06-11/doc-iniaztwk5483464.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["600276","LU2328871848.SGD","LU1781817850.SGD","BK0239","LU2097828714.EUR","BK0028","BK0060","LU0359202008.SGD","LU2580892789.USD","LU2097828557.USD","BK0196","LU1023057109.AUD","LU1997245094.SGD","LU1064130708.USD","LU2097828805.USD","LU0405327494.USD","LU2580892862.HKD","TACI","LU2148510915.USD","LU1820825898.SGD","LU0359201612.USD","BK0183","LU2543165471.USD","LU2097828631.EUR","LU1255011170.USD","01276","LU1064131003.USD","LU1580142542.USD","LU0359201885.HKD","BK0012","LU1328615791.USD","LU2488822045.USD","LU0405327148.USD","LU1997244956.HKD","LU1969619763.USD","LU1997245177.USD","LU2097828474.EUR","BK1191","LU2289578879.USD","LU2495084118.USD","BK0188","LU1655091616.SGD","LU1146622755.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642470626","title":"恒瑞医药三款新药获批临床，创新研发再添新进展｜医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2642470626","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642470626?lang=zh_cn&edition=full","pubTime":"2026-06-11 09:31","pubTimestamp":1781141460,"startTime":"0","endTime":"0","summary":"截至6月10日收盘，市场全天震荡调整，沪深两市成交额2.62万亿元。医药ETF（512120）上涨1.53%，港股通生物科技ETF（159102）上涨1.40%。相关个股中，恒瑞医药上涨1.36%、药明康德上涨3.81%、片仔癀上涨0.46%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606113767626750.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606113767626750.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0359202008.SGD","BK1515","BK0012","BK1161","BK0188","LU0359201612.USD","LU1997245177.USD","LU2328871848.SGD","LU0359201885.HKD","BK0183","01276","LU2097828474.EUR","LU2097828631.EUR","BK0028","LU2495084118.USD","LU1146622755.USD","LU1023057109.AUD","LU1997244956.HKD","09939","LU1064130708.USD","LU2580892862.HKD","BK0060","LU2580892789.USD","LU1781817850.SGD","LU2097828714.EUR","LU1655091616.SGD","LU1580142542.USD","BK0196","BK1191","LU0405327148.USD","LU1997245094.SGD","LU2148510915.USD","LU2488822045.USD","LU0405327494.USD","LU2289578879.USD","159938","LU2097828557.USD","LU1328615791.USD","LU1969619763.USD","BK1574","LU2543165471.USD","600276","LU2097828805.USD","LU1255011170.USD","LU1820825898.SGD","BK0239","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642442317","title":"恒瑞医药(01276)6月10日斥资46.04万元回购1万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2642442317","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642442317?lang=zh_cn&edition=full","pubTime":"2026-06-10 17:29","pubTimestamp":1781083796,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，于2026年6月10日，该公司斥资46.04万元回购1万股A股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452604.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0405327494.USD","LU2495084118.USD","LU1146622755.USD","LU0359201885.HKD","LU1064131003.USD","BK0239","LU2289578879.USD","LU2097828631.EUR","LU1969619763.USD","LU1997245094.SGD","LU2328871848.SGD","LU1997244956.HKD","LU2097828557.USD","LU1580142542.USD","399300","BK1191","LU1064130708.USD","LU2580892789.USD","LU1328615791.USD","BK0196","LU1820825898.SGD","LU2097828474.EUR","BK0060","LU0359202008.SGD","01276","LU0405327148.USD","LU1255011170.USD","LU2580892862.HKD","LU0359201612.USD","LU1023057109.AUD","600276","LU2543165471.USD","BK0188","LU1655091616.SGD","LU2148510915.USD","LU2488822045.USD","LU1997245177.USD","LU2097828714.EUR","LU2097828805.USD","BK0028","159982","LU1781817850.SGD","BK0012","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642679744","title":"恒瑞医药：2025年公司实现营业收入316.29亿元，同比增长13.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2642679744","media":"证券日报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642679744?lang=zh_cn&edition=full","pubTime":"2026-06-09 19:54","pubTimestamp":1781006040,"startTime":"0","endTime":"0","summary":"证券日报网讯6月9日，恒瑞医药在互动平台回答投资者提问时表示，公司始终高度重视全体股东利益，致力于发展好主营业务，以扎实的经营基本面维护公司长期价值，从而以更好的发展回馈股东。（1）公司经营业绩稳步提升，整体发展态势持续向好。2025年全年，公司实现营业收入316.29亿元，同比增长13.02%；归属于上市公司股东的净利润77.11亿元，同比增长21.69%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606093765312960.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["600276","01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642466820","title":"恒瑞医药及子公司三款药物获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2642466820","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642466820?lang=zh_cn&edition=full","pubTime":"2026-06-09 17:25","pubTimestamp":1780997100,"startTime":"0","endTime":"0","summary":"6月9日，恒瑞医药（600276/01276）发布公告，公司及子公司山东盛迪医药有限公司、广东恒瑞医药有限公司近日收到HRS-6209胶囊、HRS-8080片、HRS-9813胶囊的《药物临床试验批准通知书》，将于近期开展临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606093765192426.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0196","LU1997244956.HKD","LU2543165471.USD","BK0060","LU2097828805.USD","LU1820825898.SGD","BK0012","LU2097828474.EUR","LU2289578879.USD","LU2488822045.USD","BK0028","01276","LU1580142542.USD","LU1655091616.SGD","LU2328871848.SGD","LU2580892862.HKD","LU1997245094.SGD","LU0359201612.USD","600276","LU2097828557.USD","LU1997245177.USD","LU1969619763.USD","LU1023057109.AUD","LU2097828631.EUR","LU1064130708.USD","LU1781817850.SGD","BK1191","LU0359201885.HKD","LU1146622755.USD","LU1255011170.USD","LU0405327494.USD","BK0183","BK0239","LU2148510915.USD","LU0405327148.USD","LU1328615791.USD","BK0188","LU2097828714.EUR","LU2580892789.USD","LU0359202008.SGD","LU1064131003.USD","LU2495084118.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642146314","title":"恒瑞医药(01276)6月9日斥资319.36万元回购7万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2642146314","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642146314?lang=zh_cn&edition=full","pubTime":"2026-06-09 16:49","pubTimestamp":1780994962,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，于2026年6月9日，该公司斥资人民币319.36万元回购7万股A股股份，每股回购价人民币45.3-45.82元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451969.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1255011170.USD","LU2488822045.USD","BK0196","LU2580892789.USD","LU2289578879.USD","LU2543165471.USD","01276","LU1580142542.USD","LU0359202008.SGD","LU2097828631.EUR","LU1655091616.SGD","LU1146622755.USD","LU2580892862.HKD","BK0188","LU2097828805.USD","LU0405327494.USD","LU1969619763.USD","399300","BK0012","LU1997245177.USD","BK0183","LU1997244956.HKD","BK0060","LU1064130708.USD","LU2328871848.SGD","LU1781817850.SGD","LU2495084118.USD","LU0405327148.USD","LU0359201612.USD","LU1997245094.SGD","LU1328615791.USD","LU1023057109.AUD","600276","LU0359201885.HKD","LU2097828474.EUR","BK1191","LU1064131003.USD","LU2097828557.USD","LU1820825898.SGD","LU2148510915.USD","BK0239","LU2097828714.EUR","BK0028","159982"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641029491","title":"恒瑞医药(01276)6月8日斥资2042.57万元回购44.4万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2641029491","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641029491?lang=zh_cn&edition=full","pubTime":"2026-06-08 16:21","pubTimestamp":1780906880,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，于2026年6月8日，该公司斥资2042.57万元回购44.4万股A股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451358.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0359201885.HKD","LU2097828474.EUR","LU2097828631.EUR","LU1146622755.USD","LU0359202008.SGD","LU1255011170.USD","LU2495084118.USD","159982","LU1023057109.AUD","399300","BK0183","BK0196","LU2488822045.USD","LU2580892789.USD","LU1820825898.SGD","LU2097828805.USD","LU0405327494.USD","LU1064130708.USD","BK0188","LU1997245094.SGD","LU2148510915.USD","LU1997245177.USD","BK1191","01276","LU2097828557.USD","BK0012","LU0359201612.USD","LU2580892862.HKD","LU1781817850.SGD","LU2289578879.USD","BK0028","LU1064131003.USD","LU1997244956.HKD","LU1328615791.USD","LU2097828714.EUR","LU1655091616.SGD","BK0239","LU1969619763.USD","BK0060","LU1580142542.USD","LU2543165471.USD","LU0405327148.USD","600276","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641619989","title":"港股异动 | 恒瑞医药(01276)涨超5% “双艾”组合联合TACE治疗不可切除肝癌Ⅲ期研究结果亮相ASCO年会","url":"https://stock-news.laohu8.com/highlight/detail?id=2641619989","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641619989?lang=zh_cn&edition=full","pubTime":"2026-06-05 09:55","pubTimestamp":1780624500,"startTime":"0","endTime":"0","summary":"消息面上，据恒瑞医药官微消息，近日，在ASCO 2026年会上，公司创新药“双艾”组合联合经动脉化疗栓塞术对比单纯TACE治疗不可切除肝细胞癌的全国多中心、随机对照、III期研究亮相口头报告环节。该研究为这一“TACE联合靶免”治疗策略在uHCC中的应用提供了有力的循证支持。基于该研究，“双艾”组合联合TACE治疗不可切除的肝细胞癌的上市许可申请已于2026年年初获国家药监局受理。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450542.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0196","LU2097828474.EUR","LU1997244956.HKD","LU1064130708.USD","BK0183","LU2495084118.USD","LU1255011170.USD","BK0028","LU2097828805.USD","LU0405327148.USD","VXUS","BK4588","BK0012","LU0405327494.USD","LU1146622755.USD","LU1820825898.SGD","LU2580892862.HKD","LU1997245177.USD","LU2543165471.USD","LU2289578879.USD","BK0188","TACE","LU2097828631.EUR","LU1969619763.USD","LU2148510915.USD","LU0359201612.USD","LU1655091616.SGD","LU2097828557.USD","BK4585","LU2328871848.SGD","01276","LU1064131003.USD","LU1580142542.USD","BK0060","600276","LU0359202008.SGD","LU1328615791.USD","BK1191","LU1781817850.SGD","LU1997245094.SGD","LU2097828714.EUR","LU2580892789.USD","LU2488822045.USD","LU1023057109.AUD","LU0359201885.HKD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640155910","title":"恒瑞医药(01276)6月4日斥资1982.37万元回购42万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2640155910","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640155910?lang=zh_cn&edition=full","pubTime":"2026-06-04 17:18","pubTimestamp":1780564719,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，于2026年6月4日，该公司斥资人民币1982.37万元回购42万股A股股份，每股回购价人民币46.7-47.7元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450154.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1255011170.USD","LU2488822045.USD","BK0196","LU2580892789.USD","LU2289578879.USD","LU2543165471.USD","01276","LU1580142542.USD","LU0359202008.SGD","LU2097828631.EUR","LU1655091616.SGD","LU1146622755.USD","LU2580892862.HKD","BK0188","LU2097828805.USD","LU0405327494.USD","LU1969619763.USD","399300","BK0012","LU1997245177.USD","BK0183","LU1997244956.HKD","BK0060","LU1064130708.USD","LU2328871848.SGD","LU1781817850.SGD","LU2495084118.USD","LU0405327148.USD","LU0359201612.USD","LU1997245094.SGD","LU1328615791.USD","LU1023057109.AUD","600276","LU0359201885.HKD","LU2097828474.EUR","BK1191","LU1064131003.USD","LU2097828557.USD","LU1820825898.SGD","LU2148510915.USD","BK0239","LU2097828714.EUR","BK0028","159982"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640977122","title":"美团、京东、阿里、腾讯，集体下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2640977122","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640977122?lang=zh_cn&edition=full","pubTime":"2026-06-03 16:32","pubTimestamp":1780475520,"startTime":"0","endTime":"0","summary":"6月3日，香港恒生指数收跌1.56%，恒生科技指数跌2.74%。\n\n 科网股普跌，金蝶国际跌超7%，美团跌近6%，京东集团跌超4%，腾讯控股、阿里巴巴跌超3%。\n\n 生物医药板块下挫，药明生物、药明合联、恒瑞医药均大跌7%。\n编辑丨瑜见\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：孙同怀","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/wm/2026-06-03/doc-iniacnun2375144.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-06-03/doc-iniacnun2375144.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1146622755.USD","LU1813983027.USD","LU2039709279.SGD","LU2362540622.SGD","LU2462611646.USD","LU0370786039.SGD","LU0648948544.HKD","LU2237443382.USD","LU1226288170.HKD","IE0003851619.USD","LU0784639295.USD","03088","LU0011963245.USD","LU0417516902.SGD","LU0348825331.USD","LU0211977185.USD","LU1115378108.SGD","LU1794554557.SGD","LU0210527791.USD","09067","LU0163747925.USD","01276","02833","LU0819121731.USD","LU0140636845.USD","LU0173614495.USD","LU0164872284.USD","BABA","LU0865486749.SGD","02800","BK1517","LU1023057109.AUD","LU0348723411.USD","LU0871576103.HKD","LU1688375341.USD","HK0000320264.USD","LU0831103253.SGD","MPNGY","IE00B3M56506.USD","LU1770036033.HKD","LU0348814723.USD","LU1196710864.SGD","SGXZ81514606.USD","03037","LU1691799644.USD","BK4558","LU0650527681.SGD","LU0455707207.USD","LU0164880469.USD","LU2279701549.SGD","LU0261950983.USD","LU1785774172.SGD","LU0348827113.USD","LU1316542783.SGD","LU0231483743.USD","IE00B29SXG58.USD","BK4502","LU0828237510.HKD","LU1282649810.SGD","LU0572944931.SGD","LU2148611432.USD","LU0345776255.USD","BABX","LU0540923850.HKD","LU0553294199.USD","LU0307460666.USD","LU0633140560.USD","LU0106259558.USD","LU0449515922.USD","IE00BZ08YT58.USD","LU1196710351.USD","LU1820825898.SGD","LU0143863784.USD","LU0289960550.SGD","LU0072913022.USD","LU2237443622.USD","LU1808992512.USD","LU0737861772.HKD","BK4533","BK4588","LU2580892789.USD","LU0441854154.USD","IE00BQXX3D17.EUR","LU0516423174.USD","BABO","LU0210533765.USD","LU0828237940.HKD","BK1142","LU1720050803.USD","BK1591","LU1226288253.USD","LU1255011170.USD","LU0588546209.SGD","SG9999002463.SGD","07552","LU2125910500.SGD","LU0819123356.HKD","BK4565","LU2097828714.EUR","IE0034224299.USD","LU1880383440.USD","BK1583","LU0348788117.USD","LU0791591158.USD","SG9999018857.SGD","LU1251922891.USD","SG9999001051.SGD","LU0315178854.USD","LU1769817179.HKD","LU1831875114.USD","SG9999001689.USD","LU0384037296.USD","LU0293314216.USD","LU1868837565.USD","BK4587","LU1152091168.USD","LU2449936058.SGD","BK1618","LU0229945570.USD","LU2237443895.HKD","BK0188","SGXZ99366536.SGD","BK4122","LU0823397285.USD","LU2778985437.USD","03690","LU0531971595.HKD","LU2097828474.EUR","SG9999004220.SGD","LU0067412154.USD","LU2328871848.SGD","LU0594300179.USD","LU0043850808.USD","LU1328277881.USD","LU0348783233.USD","LU0823413660.USD","LU0203345920.USD","LU1366334578.USD","LU0456842615.SGD","IE0001KFT4U8.USD","SG9999002562.SGD","HMTD.SI","LU0244354667.USD","LU2495084118.USD","LU2237443978.SGD","LU0117844026.USD","LU2265009873.SGD","LU1044875133.USD","LU0327786744.USD","BK0060","LU0611395673.USD","07500","LU1868838027.USD","LU0823041008.USD","LU1515016050.SGD","LU0886674414.USD","03423","LU1046421795.USD","LU1226287792.SGD","LU1008478684.HKD","SG9999001903.USD","07226","513600","LU1044876610.USD","LU1439103000.SGD","SGXZ31699556.SGD","LU1814569148.SGD","LU1997244956.HKD","BK4614","LU0417516738.SGD","LU0049853897.USD","LU0862451837.USD","IE00BZ08YR35.GBP","BK4554","LU1769817096.USD","LU0214875030.USD","BK4504","LU1328615791.USD","LU0791590937.USD","LU1951186391.HKD","LU2488822045.USD","LU1048484197.HKD","LU0320764755.SGD","BK4526","LU2237443465.HKD","LU2087589342.USD","LU0882747503.HKD","BK1249","LU0516422952.EUR","LU0661504455.SGD","HSI","BK4505","SG9999015986.USD","IE00B067MR52.USD","LU0862451753.SGD","IE00B543WZ88.USD","600276","LU1629966141.USD","LU0414403682.SGD","LU0143863198.USD","BK4548","LU0264606111.USD","LU1051769294.HKD","LU2476274720.SGD","LU0348784397.USD","LU0516423091.SGD","LU0348783662.USD","LU1810669033.SGD","LU2177674079.SGD","SG9999001093.SGD","LU0314109678.HKD","LU0856984785.SGD","BK4585","LU0868486357.SGD","LU0039217434.USD","LU0326950275.SGD","BK1575","LU0640798160.USD","BK4543","IE0031814852.USD","LU0541502299.USD","LU1196710195.USD","LU0608807946.USD","BK1589","LU1997245177.USD","BBYY","BK1609","LU0254981946.USD","LU0823426480.USD","LU0310800965.SGD","LU0052750758.USD","LU0054237671.USD","LU0589944569.HKD","LU1242518931.SGD","IE00B031HY20.USD","03115","SG9999001226.SGD","BK4607","SG9999014880.SGD","LU0169518387.USD","03417","LU0918141705.HKD","09618","LU2152927971.USD","LU0096374516.USD","LU0642271901.SGD","03067","LU0979878070.USD","SG9999015978.USD","LU0608807433.USD","LU2251237488.HKD","LU0315179316.USD","SG9999014914.USD","LU0417516571.SGD","LU0080751232.USD","LU0326948709.USD","LU1655091459.SGD","IE00BQXX3C00.GBP","BK4534","07300","LU1105468828.SGD","LU2476274308.USD","LU0320764243.SGD","LU0683595622.HKD","LU0127658192.USD","BK0183","MCHmain","LU0329678170.USD","LU0165289439.USD","LU1224709979.USD","LU0593848301.USD","LU0149721374.USD","LU2125910849.SGD","LU2580892862.HKD","LU0502904849.HKD","LU0898667661.SGD","HK0000914686.HKD","LU1235295612.USD","LU0509642566.USD","IE0032431581.USD","LU1211504680.USD","LU0949170772.SGD","BK1521","BK4220","KBAB","LU0823039010.USD","LU1102505929.USD","LU0181495838.USD","LU0359202008.SGD","LU1267930227.SGD","LU1323998911.USD","LU0786609619.USD","LU0228367735.SGD","SG9999015945.SGD","LU1366334651.USD","LU0072462343.USD","LU0577902298.EUR","LU0048388663.USD","LU2399975544.HKD","LU0541501648.USD","LU1439102457.SGD","BK1141","SG9999007991.SGD","LU0531970944.HKD","LU0048597586.USD","IE00BPRC5H50.USD","LU0577902371.SGD","LU0828238088.HKD","LU0359201885.HKD","LU0211331839.USD","LU0164865239.USD","BK0196","SG9999017495.SGD","LU1880383366.USD","LU0320764599.SGD","LU0107464264.USD","LU0708995583.HKD","LU0348816934.USD","LU0823397103.USD","LU2257852520.SGD","LU1804176565.USD","IE00B031J352.USD","LU0700851271.USD","LU1102505762.USD","LU1997245094.SGD","SG9999001846.SGD","LU2362541273.HKD","LU0516422366.SGD","IE00B031HW06.USD","LU1655091616.SGD","LU1282649141.HKD","BABU","LU0823426308.USD","LU2498475776.HKD","LU0210526637.USD","HK0000151867.HKD","SG9999002828.SGD","LU0251143458.SGD","IE00BF5LJ272.USD","03419","LU2051468812.USD","LU0431992006.USD","LU0545039389.USD","BK1233","LU1868837722.USD","LU0348735423.USD","LU0128522157.USD","LU1282651121.HKD","LU0054450605.USD","LU0543330483.HKD","LU0405327494.USD","LU1044874839.SGD","LU2237443549.SGD","LU0287142896.SGD","SG9999000327.SGD","IE00BZ08YS42.EUR","LU1226287529.USD","LU0469268626.HKD","IE00B8L5B284.USD","LU0878005551.USD","LU0651946864.USD","LU2251237306.USD","IE00B0169L03.USD","LU1917777945.USD","LU0572940350.SGD","LU0878004406.USD","LU0577902454.USD","LU0823038988.USD","IE0003895053.USD","LU1642822792.SGD","BK1526","LU0738911758.USD","LU0049112450.USD","LU0449509016.USD","LU1718418525.SGD","IE0008369823.USD","LU2106854487.HKD","LU0918141887.USD","BK1502","LU1224444064.USD","BK4581","LU2023250504.SGD","09115","LU1064131003.USD","LU0588545490.SGD","SGXZ51526630.SGD","LU0516422440.USD","BK1608","LU0501845795.SGD","LU0329678337.USD","IE0008368742.USD","LU0259732245.USD","LU2226246903.HKD","LU0047713382.USD","HTCD.SI","HSTECH","LU0737861699.HKD","BK4524","LU1974910355.USD","89618","BK1604","LU0588545730.USD","LU1883866441.USD","HK0000306701.USD","02269","LU1282649067.USD","LU0061477393.USD","LU0543330566.HKD","SG9999015952.SGD","HK0000914660.USD","LU0192582467.USD","07200","MHImain","LU0269904917.USD","LU0396098781.USD","IE00BFMHRM44.USD","LU1051768304.USD","LU1956131251.USD","LU0117841782.USD","LU0588545904.SGD","BK1531","LU1568876251.USD","SG9999014674.SGD","BK0012","LU0672654166.SGD","BK1095","LU1504937902.USD","LU1282648689.USD","LU0235996351.USD","LU0577902538.SGD","03033","LU0070217475.USD","LU0499858438.USD","LU0348805143.USD","LU0708995153.HKD","LU0345769128.USD","LU2289578879.USD","LU1807302812.USD","SG9999014898.SGD","LU1048596156.SGD","LU1823568750.SGD","LU0084288322.USD","LU2008162690.USD","BK1588","LU1481107354.HKD","LU2362541513.USD","IE00B97KM107.HKD","LU1152091754.HKD","LU3063872942.SGD","LU1242518857.USD","HK0000352382.USD","BK0028","BK1576","LU0128522744.USD","LU1981816686.USD","BK4527","IE0009570106.USD","LU2242644610.SGD","LU1048588211.SGD","BK4575","LU1226288097.SGD","LU1719994722.HKD","LU0029875118.USD","LU0132412106.USD","LU0052756011.USD","LU0880133367.SGD","LU1733274390.USD","IE0008368411.USD","IE00B0169N27.USD","LU2247934214.USD","SG9999000418.SGD","IE0032834883.USD","BK1619","LU2133065610.SGD","BK1516","LU0577902611.USD","SGXZ90724238.SGD","LU0456827905.SGD","LU0463099449.HKD","LU1734074674.USD","BK1615","HK0000320223.HKD","WXXWY","LU0594300419.USD","LU0607220059.USD","IE00B8HQ1Z84.USD","LU1969619763.USD","BK1610","LU1580142542.USD","SG9999001069.SGD","LU0561508036.HKD","LU1064130708.USD","LU0106959298.USD","HK0000352291.HKD","BK1586","JD","LU2148510915.USD","LU0572939691.SGD","LU0345769631.USD","TCEHY","LU1303224171.USD","09088","IE0003795394.USD","LU1282651048.USD","LU1781817850.SGD","LU0823413587.USD","LU0051755006.USD","LU0605514214.HKD","LU0651947912.USD","LU0228659784.USD","LU1960683339.HKD","LU0738912210.USD","LU2097828805.USD","83115","LU1961090484.USD","03032","LU1675838814.USD","LU2294711473.HKD","82800","LU1568876335.HKD","LU0488056044.USD","LU2293587155.HKD","IE00B0JY6N72.USD","BK0239","BK4538","SG9999018865.SGD","LU1046422090.SGD","LU0196878994.USD","LU1235294995.USD","LU1725190679.HKD","LU0873338254.USD","LU0128525689.USD","LU2317271919.USD","LU1188198961.HKD","SG9999013353.USD","BK4503","LU0175139822.USD","SG9999000459.SGD","IE00BGV7N243.SGD","LU0985320562.USD","LU2097828557.USD","SG9999006514.SGD","LU1993786604.SGD","LU2097828631.EUR","LU0634319403.HKD","HK0000306685.HKD","GB00BDT5M118.USD","LU0029874905.USD","BK4579","LU1770034418.SGD","LU0106252389.USD","LU1003077747.HKD","LU0188438112.USD","IE00B5MMRT66.SGD","LU0972618739.USD","BK4535","LU0633140727.USD","LU0359201612.USD","SG9999003461.SGD","LU0405327148.USD","HK0001040143.USD","LU0823040885.USD","LU0890818403.SGD","LU1733274473.HKD","LU0797268264.HKD","LU0345775950.USD","LU0048580855.USD","LU0328353924.USD","02837","BK4531","LU1226287875.USD","LU0261947096.USD","HK0001040168.HKD","SG9999014906.USD","LU0499858602.USD","LU2045819591.USD","LU0251144936.SGD","00700","BABW","LU0821914370.USD","IE00BQXX3F31.USD","LU0203347892.USD","09988","SG9999006597.SGD","LU0675040207.SGD","HHImain","LU0149534421.HKD","LU0456846285.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640491601","title":"恒瑞医药(01276)：截至5月末公司累计回购A股股份1205.62万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2640491601","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640491601?lang=zh_cn&edition=full","pubTime":"2026-06-02 17:13","pubTimestamp":1780391596,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，2026年5月，公司通过上海证券交易所交易系统以集中竞价交易方式回购股份0股。截至2026年5月31日，公司本次股份回购方案累计通过上海证券交易所交易系统以集中竞价交易方式回购股份1,205.62万股，已回购股份占公司总股本的比例为0.18%，购买的最高价为人民币70.00元/股，最低价为人民币53.52元/股，已支付的总金额为人民币77,198.09万元(不含交易费用)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1449098.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0060","BK0239","LU1580142542.USD","LU2148510915.USD","LU1328615791.USD","BK0183","LU1781817850.SGD","BK0012","LU1997245094.SGD","LU2580892789.USD","LU1023057109.AUD","LU1064130708.USD","BK0188","LU2097828805.USD","LU2289578879.USD","399300","01276","LU0359201885.HKD","159982","LU1146622755.USD","LU0359202008.SGD","LU1820825898.SGD","LU2543165471.USD","LU2097828714.EUR","BK0028","LU0405327148.USD","LU2495084118.USD","LU1255011170.USD","LU1969619763.USD","BK0196","LU2328871848.SGD","LU1064131003.USD","LU2580892862.HKD","BK1191","LU2097828557.USD","LU2097828631.EUR","LU0405327494.USD","LU1997244956.HKD","LU2488822045.USD","LU2097828474.EUR","LU0359201612.USD","600276","LU1655091616.SGD","LU1997245177.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640167049","title":"恒瑞医药累计回购1206万股 金额7.72亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2640167049","media":"财中社","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640167049?lang=zh_cn&edition=full","pubTime":"2026-06-02 17:07","pubTimestamp":1780391220,"startTime":"0","endTime":"0","summary":"6月2日，恒瑞医药（600276/01276）发布公告，截至2026年5月31日，公司已回购1206万股，占总股本的0.18%，累计回购金额为7.72亿元，回购价格区间为53.52元/股至70元/股。2026年一季度，恒瑞医药实现收入81.41亿元，归母净利润22.82亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606023757608896.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1655091616.SGD","LU2289578879.USD","LU1997244956.HKD","LU2580892862.HKD","LU1023057109.AUD","LU1328615791.USD","LU1146622755.USD","LU1580142542.USD","LU2580892789.USD","LU1997245177.USD","LU1969619763.USD","LU2543165471.USD","BK0060","BK0239","LU2097828474.EUR","BK0196","BK0183","LU2495084118.USD","LU1064131003.USD","LU0359201612.USD","LU2328871848.SGD","BK0028","LU1820825898.SGD","LU2097828631.EUR","LU1997245094.SGD","LU1255011170.USD","LU1781817850.SGD","LU2097828805.USD","LU0359202008.SGD","LU1064130708.USD","01276","LU0405327494.USD","LU0405327148.USD","LU2097828557.USD","LU2488822045.USD","BK1191","LU0359201885.HKD","LU2148510915.USD","600276","LU2097828714.EUR","BK0012","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640317951","title":"恒瑞医药：公司坚持科技创新与国际化发展战略，致力于发展好主营业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2640317951","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640317951?lang=zh_cn&edition=full","pubTime":"2026-06-01 20:01","pubTimestamp":1780315260,"startTime":"0","endTime":"0","summary":"证券日报网讯6月1日，恒瑞医药在互动平台回答投资者提问时表示，二级市场股价波动受多种因素影响，公司日常经营管理和业务状况正常。公司坚持科技创新与国际化发展战略，致力于发展好主营业务，促进公司业绩可持续增长，以更好的发展回馈股东。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606013756213975.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["600276","LU2328871848.SGD","LU1781817850.SGD","BK0239","LU2097828714.EUR","BK0028","BK0060","LU0359202008.SGD","LU2580892789.USD","LU2097828557.USD","BK0196","LU1023057109.AUD","LU1997245094.SGD","LU1064130708.USD","LU2097828805.USD","LU0405327494.USD","LU2580892862.HKD","LU2148510915.USD","LU1820825898.SGD","LU0359201612.USD","BK0183","LU2543165471.USD","LU2097828631.EUR","LU1255011170.USD","01276","LU1064131003.USD","LU1580142542.USD","LU0359201885.HKD","BK0012","LU1328615791.USD","LU2488822045.USD","LU0405327148.USD","LU1997244956.HKD","LU1969619763.USD","LU1997245177.USD","LU2097828474.EUR","BK1191","LU2289578879.USD","LU2495084118.USD","BK0188","LU1655091616.SGD","LU1146622755.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639676739","title":"恒瑞医药：公司将继续大力推进“科技创新”和“国际化”两大发展战略","url":"https://stock-news.laohu8.com/highlight/detail?id=2639676739","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639676739?lang=zh_cn&edition=full","pubTime":"2026-05-29 22:59","pubTimestamp":1780066740,"startTime":"0","endTime":"0","summary":"证券日报网讯5月29日，恒瑞医药在互动平台回答投资者提问时表示，公司将继续大力推进“科技创新”和“国际化”两大发展战略，稳步推进研发创新和制剂产品的国际化。同时，也将着力于产品结构的优化提升，通过产品创新升级和多元化产品管线的拓展推动公司的持续发展，促进公司业绩可持续增长，以更好的发展回馈股东。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605293754793698.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2580892862.HKD","LU2097828714.EUR","LU2328871848.SGD","LU1997245177.USD","LU0405327148.USD","LU1064131003.USD","BK0239","BK0060","LU0359201885.HKD","BK0183","LU1328615791.USD","LU1064130708.USD","LU2097828474.EUR","BK0188","LU2580892789.USD","BK0028","BK0012","LU1997245094.SGD","LU1146622755.USD","LU1997244956.HKD","LU2543165471.USD","LU2148510915.USD","600276","LU0405327494.USD","LU2097828805.USD","LU1580142542.USD","LU2495084118.USD","LU1781817850.SGD","LU1255011170.USD","LU2488822045.USD","LU2097828631.EUR","BK0196","LU2289578879.USD","LU0359202008.SGD","LU1655091616.SGD","LU1820825898.SGD","BK1191","LU0359201612.USD","LU1969619763.USD","01276","LU1023057109.AUD","LU2097828557.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639676731","title":"恒瑞医药：公司本轮回购期限为自2025年8月20日董事会审议通过回购股份方案之日起12个月以内，目前本次回购尚未结束","url":"https://stock-news.laohu8.com/highlight/detail?id=2639676731","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639676731?lang=zh_cn&edition=full","pubTime":"2026-05-29 22:58","pubTimestamp":1780066680,"startTime":"0","endTime":"0","summary":"证券日报网讯5月29日，恒瑞医药在互动平台回答投资者提问时表示，为保障2025年年度权益分派方案实施，公司本轮回购工作自权益分派实施筹备工作启动之日至权益分派实施完毕期间暂停。公司本轮回购期限为自2025年8月20日董事会审议通过回购股份方案之日起12个月以内，目前本次回购尚未结束。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605293754790498.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1655091616.SGD","LU2289578879.USD","LU1997244956.HKD","LU2580892862.HKD","LU1023057109.AUD","LU1328615791.USD","LU1146622755.USD","LU1580142542.USD","LU2580892789.USD","LU1997245177.USD","LU1969619763.USD","LU2543165471.USD","BK0060","BK0239","LU2097828474.EUR","BK0196","BK0183","LU2495084118.USD","LU1064131003.USD","LU0359201612.USD","LU2328871848.SGD","BK0028","LU1820825898.SGD","LU2097828631.EUR","LU1997245094.SGD","LU1255011170.USD","LU1781817850.SGD","LU2097828805.USD","LU0359202008.SGD","LU1064130708.USD","01276","LU0405327494.USD","LU0405327148.USD","LU2097828557.USD","LU2488822045.USD","BK1191","LU0359201885.HKD","LU2148510915.USD","600276","LU2097828714.EUR","BK0012","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639676986","title":"恒瑞医药：公司目前已在中国获批上市25款1类创新药、5款2类新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2639676986","media":"证券日报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639676986?lang=zh_cn&edition=full","pubTime":"2026-05-29 22:48","pubTimestamp":1780066080,"startTime":"0","endTime":"0","summary":"证券日报网讯5月29日，恒瑞医药在互动平台回答投资者提问时表示，公司坚持科技创新战略，目前已在中国获批上市25款1类创新药、5款2类新药，另有100多个自主创新产品正在临床开发，400余项临床试验在国内外开展。经营业绩方面，创新成果转化高效赋能，创新药销售引领业绩增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605293754780227.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2097828631.EUR","600276","LU1064130708.USD","LU2328871848.SGD","LU1064131003.USD","06978","LU0359202008.SGD","LU0405327494.USD","LU2543165471.USD","LU1655091616.SGD","LU1997244956.HKD","LU2495084118.USD","LU1580142542.USD","BK0196","LU2097828557.USD","159992","LU2097828714.EUR","LU1146622755.USD","LU1328615791.USD","LU2148510915.USD","BK0183","BK0239","BK0028","LU0359201612.USD","LU1997245094.SGD","LU1820825898.SGD","LU2580892789.USD","BK0188","LU1255011170.USD","BK1191","BK1161","LU2097828474.EUR","IPOS","BK0060","BK0012","LU2289578879.USD","LU1969619763.USD","LU1023057109.AUD","LU0359201885.HKD","LU2488822045.USD","01276","LU0405327148.USD","BK1574","LU1781817850.SGD","LU2097828805.USD","LU1997245177.USD","LU2580892862.HKD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1781757864786,"stockEarnings":[{"period":"1week","weight":-0.0004},{"period":"1month","weight":-0.1001},{"period":"3month","weight":-0.1577},{"period":"6month","weight":-0.2246},{"period":"1year","weight":-0.0898},{"period":"ytd","weight":-0.2079}],"compareEarnings":[{"period":"1week","weight":0.0288},{"period":"1month","weight":-0.0057},{"period":"3month","weight":0.0253},{"period":"6month","weight":0.0559},{"period":"1year","weight":0.2128},{"period":"ytd","weight":0.0351}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏恒瑞医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"458309人(较上一季度增加1.93%)","perCapita":"13918股","listingDate":"2000-10-18","address":"江苏省连云港市连云区经济技术开发区黄河路38号","registeredCapital":"663719万元","survey":" 江苏恒瑞医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是马来酸吡咯替尼片、注射用卡瑞利珠单抗、瑞维鲁胺片、海曲泊帕乙醇酰胺片、羟乙磺酸达尔西利片、碘佛醇注射液。自2019年起，公司连续七年跻身美国《制药经理人》(PharmExec)杂志评选的全球制药企业50强榜单。","listedPrice":11.98},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恒瑞医药(600276)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恒瑞医药(600276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恒瑞医药,600276,恒瑞医药股票,恒瑞医药股票老虎,恒瑞医药股票老虎国际,恒瑞医药行情,恒瑞医药股票行情,恒瑞医药股价,恒瑞医药股市,恒瑞医药股票价格,恒瑞医药股票交易,恒瑞医药股票购买,恒瑞医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恒瑞医药(600276)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恒瑞医药(600276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}